Kohei Shitara, Medical Oncologist at National Cancer Center Hospital East, Japan, shared an article on X he and his colleagues authored:
“Pleased to share P2 results of futibatinib for FGFR2-amplified gastric cancer: ORR 17.9%. Shows some activity but underscores need for better options. Eagerly awaiting P3 chemo + bemarituzumab data.”
Authors: Taroh Satoh et al.
